Plidan Compuesto is commonly used for managing symptoms related to physical discomfort where both pain and smooth muscle spasm occur, offering short-term supportive assistance during acute episodes. It is generally applied in scenarios where symptoms create noticeable interference with daily stability. This formulation is relevant within therapeutic domains that involve acute, visceral discomfort. This formulation is relevant for addressing pain in conditions like renal colic and moderately severe attacks.

The primary benefit contributes to improved comfort during periods of heightened symptoms and may assist with easing the overall symptom load. The core use is centered on conditions characterized by spasms and pain within the digestive, urological, and gynecological systems. Common symptomatic applications are relevant for easing distress associated with conditions such as renal colic, hepatic colic, cholecystitis, and dysmenorrhea.

“It is generally used for managing symptoms related to physical discomfort where both pain and smooth muscle spasm occur.”

---

Quick Fact: Relief for Visceral Spasm and Acute Pain

Symptom Domain	Typical Conditions	General Benefit
Spastic Colic	Kidney stones, Gallbladder inflammation, Colitis, Severe menstrual cramps	Helps patients cope more steadily with symptom fluctuations and supports general well-being.

Official Regulatory Eligibility and Restrictions

Plidan Compuesto is subject to eligibility rules reflecting its composition as a fixed-dose combination of an NSAID (Clonixin) and an Antispasmodic (Pargeverine). Use is generally limited to the adult population that does not possess specific comorbidities.

Eligibility Classification	Population / Condition
Absolute Contraindicated Use	History of gastrointestinal bleeding, peptic ulcer, or perforation.
	Severe renal impairment or severe hepatic impairment.
	Specific ocular conditions, such as certain forms of glaucoma.
	Pregnancy during the third trimester and known hypersensitivity to any NSAID.
Not Recommended Use	Pediatric population (safety and efficacy not established).
	Lactating/Breastfeeding women and individuals in the first or second trimesters of pregnancy.
Conditional/Restricted Use	Older adults and patients with established cardiovascular disease (e.g., severe hypertension).

These regulatory classifications define eligibility based on the patient's existing health status, specifically focusing on the integrity of major organ function (hepatic, renal, GI) and life stage. The structure ensures that populations known to be at heightened risk from either active component are formally excluded from use.

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Plidan Compuesto, based on the regulatory classifications for its two active components, an NSAID (Clonixin) and an Anticholinergic (Pargeverine).

---

Classification	Details
Interaction Severity	Contraindicated Combinations are established with other Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Anticoagulants due to severe additive risks.
Interacting Categories	NSAIDs, Anticoagulants, Antiplatelet Agents, Antihypertensive Agents, Other Anticholinergic Drugs, Nephrotoxic Agents, and CYP Inducers.

---

Official Interaction Statements

• Formal Restrictions: Co-administration with other NSAIDs or with Anticoagulants/Antiplatelet Agents is subject to prohibitions, as the combination results in a pronounced, additive risk of gastrointestinal bleeding and hemorrhage.
• Pharmacokinetic Interference: The Clonixin component causes a reduction in the renal clearance of substances such as Lithium and Methotrexate, resulting in increased plasma concentrations and a heightened risk of toxicity for those co-administered drugs.
• Functional Interference: The NSAID component can reduce the antihypertensive effect of agents like Diuretics and ACE Inhibitors, impacting the co-administered drug's intended blood pressure regulation.
• Additive Effects: Co-ingestion with Alcohol or other Anticholinergic Drugs results in additive effects, increasing the potential for central nervous system (CNS) depression (e.g., drowsiness) and augmented peripheral anticholinergic effects.

The regulatory profile is structured around these two components, detailing risks from pharmacodynamic reinforcement (additive effects on bleeding, anticholinergic action) and pharmacokinetic changes (altered clearance), which together define the necessary constraints for co-administration.

How Plidan Compuesto Works

Clonixin's analgesic mechanism involves the non-selective inhibition of Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This enzyme inhibition blocks the biosynthesis of prostaglandins, which are eicosanoid mediators that sensitize peripheral nociceptors (pain nerve endings). The consequent reduction in local prostaglandin concentration results in attenuated nociceptor sensitization and modified signal transmission at the peripheral level.

Pargeverine's spasmolytic action engages two mechanisms within visceral smooth muscle. It acts as a musculotropic agent by inhibiting the influx of extracellular calcium ions ( Ca^2+), thereby interrupting excitation-contraction coupling. This is complemented by moderate antagonism at peripheral muscarinic receptors (M receptors), which reduces cholinergic contractile signaling.

These two distinct mechanisms provide complementary mechanistic action: Pargeverine induces smooth muscle relaxation, influencing the state of mechanical stress, while Clonixin modulates nociceptive input. This coordinated dual action results in simultaneous modulation of muscle tone and nociceptive pathways.

How Plidan Compuesto is Used: Official Administration Guidelines

Plidan Compuesto, a fixed-dose combination of Pargeverine and Clonixin, is approved for administration through both oral and parenteral routes, establishing a standardized protocol for its use. The medicine's official instructions govern the dosage forms, frequency, and preparation steps.

---

Administration Scope

Feature	Official Guideline
Route of Administration	Oral (tablet), Intramuscular (IM) injection, or Intravenous (IV) injection.
Standard Unit Dose	Oral: 1 to 2 tablets per dose. Parenteral: The content of both injectable ampules combined constitutes one dose.
Maximum Frequency	Oral: Up to three times daily. Parenteral: Up to four times daily.
Preparation Requirements	Injectable administration requires that the contents of Ampule I (Pargeverine) and Ampule II (Clonixin) be mixed into a single syringe immediately before use.
Procedural Conditions	Tablets must be swallowed whole (not chewed or crushed). IV administration must be conducted as a slow injection.

---

Population-Specific Administration

The oral formulation is approved for use in children over 10 years of age with the same standard adult dose (1 to 2 tablets, up to 3 times daily). For older adult patients or those with hepatic or renal function changes, the administration is advised to proceed with caution, aligning with the general use principles for its NSAID component. The medicine is designated for the short-term, as-needed management of acute episodes, guided by daily frequency limits.

These official administration guidelines ensure the medicine is delivered using specific dose ranges and routes.

Plidan Compuesto: Research Evidence / Overview of Studies

Evidence for Use in Symptomatic Relief of Acute Pain Episodes

Plidan Compuesto was studied for its use in conditions associated with acute or disruptive episodes. This research primarily involved short-term randomized controlled trials (RCTs). These studies typically compared the outcomes of patients receiving Plidan Compuesto against those receiving a placebo (an inactive substance) over observation periods that were generally limited to a few hours.

The main patient-reported outcomes describing perceived discomfort that were measured in these trials included changes in validated scoring systems, such as how patients reported perceived discomfort and the timing of documented changes in outcomes describing episodic or acute changes. Research describes patterns observed in the studies over these defined time intervals. Research highlights changes measured during the study period in populations experiencing acute pain, contributing to the broader evidence landscape related to symptom intensity or variability.

---

Long-Term Studies and Follow-Up Data

When considering the full scope of research, the majority of the controlled trials relevant in trials assessing short-term or episodic symptom patterns had limited follow-up durations. This means that long-term effects are not fully established.

Some evidence is derived from settings with varying symptom burdens, such as post-marketing observational cohort studies, which studies monitored patient experiences over periods extending up to a year. However, these types of studies provide limited insight into the sustained outcomes or the durability of response beyond the acute phase. The evidence contributes to understanding patient-reported outcomes describing perceived discomfort but does not provide extensive data on continuous use over many months or years.

---

Research Evidence in Special Populations

Research exploring short-term symptom changes generally focused on the adult population between the ages of 18 and 65. Consequently, data for certain groups remain insufficient.

Specifically, few data are available from formal, controlled trials concerning its use in pediatric patients or very elderly adults (typically those over 75). Furthermore, comparative evidence is lacking or limited for individuals with pre-existing, severe functional conditions, such as significant renal or hepatic impairment. Findings for these specific populations often rely on smaller reports, and formal data from large trials for these groups are limited.

---

Comparative Research: Plidan Compuesto vs. Placebo or Other Interventions

Plidan Compuesto was evaluated in studies comparing it to a placebo or, in some cases, to other interventions. In these trials, researchers examined patient-reported outcomes describing perceived discomfort and outcomes monitoring physiological strain or stress.

The research described patterns related to the proportion of patients where specific changes in measured outcomes were documented. Findings describe group patterns, not personal outcomes, and are based on the specific conditions under which the studies were conducted. Results apply only to the populations studied and primarily highlight changes measured during the study period relative to the comparator groups.

---

The Quality and Strength of the Evidence

The available evidence for Plidan Compuesto is derived from a combination of study types, including Phase 3 RCTs, and real-world, observational settings evaluating daily-life functioning. However, evidence quality varies across studies. The research describes how patients reported their experience during periods of increased symptom activity. While a number of controlled trials have been conducted, evidence remains limited and heterogeneous when attempting to characterize long-term outcomes or application across a very broad and diverse patient population.

---

What is Still Uncertain About Plidan Compuesto

A number of aspects related to Plidan Compuesto are not fully established, and research is ongoing. A significant area of uncertainty is the lack of extensive, long-term, randomized data; long-term effects are not fully established and follow-up durations were limited in many key trials.

Furthermore, subgroup findings are uncertain due to limited data available for key populations, including children and older adults. The evidence highlights what is known and what is still uncertain, reinforcing that research provides context but not individual predictions.

Common questions about Plidan Compuesto (FAQ)

Q: What kind of conditions is Plidan Compuesto used to treat?

A: According to the official product information, Plidan Compuesto is indicated for treating gastrointestinal and urinary spasms. These conditions involve painful, involuntary muscle contractions in the digestive or urinary systems. Regulatory documents state it is used in conditions where these painful spasms are present.

Q: Does Plidan Compuesto help with pain related to menstruation (period pain)?

A: Studies and official information indicate that Plidan Compuesto is used to treat painful conditions associated with female genital tract spasms. This indication covers conditions such as menstrual cramps (dysmenorrhea) where these painful spasms occur.

Q: Is this medication safe to use if I have a history of heart problems or arrhythmias?

A: Regulatory documents state that Plidan Compuesto is contraindicated (should not be used) in patients with tachyarrhythmias. Tachyarrhythmias are forms of heart rhythm disorder where the heart beats too fast. The medication is formally contraindicated according to the official product information for people with these specific heart conditions.

Q: Can Plidan Compuesto affect my vision?

A: Official product information lists a possible adverse reaction related to vision, specifically disturbances in ocular accommodation. This means the medication may affect the eye's ability to focus clearly, particularly on close objects. Regulatory documents mention that this potential side effect is usually temporary.

Q: Can I take Plidan Compuesto if I have a stomach ulcer?

A: According to the official product information, Plidan Compuesto is contraindicated if a person has an ulcerative disease of the gastrointestinal tract. This means people with conditions like a stomach or duodenal ulcer should not use this medication. Official sources classify its use as contraindicated under these circumstances.

Official Storage and Disposal Requirements

All storage and handling must strictly adhere to the conditions specified in the medicine's official regulatory labeling.

Storage Condition	Requirement
Temperature	Store at a temperature not more than 30 C.
Environment	Keep the medicine in a cool and dry place.
Protection	Keep in the original container and maintain it tightly closed.

---

Handling and Safety

To prevent accidental exposure, it is mandatory to keep Plidan Compuesto out of the sight and reach of children. The product must not be used after the expiration date indicated on the package. Do not use the medicine if you notice any signs of deterioration in the container or its contents.

Disposal of Unused Medicine

Official instructions strictly prohibit disposing of Plidan Compuesto in the household trash or by flushing it down drains or toilets. You must consult a pharmacist regarding the proper disposal methods for expired or unused medicine, which helps protect the environment.